Alys Pharmaceuticals Is An Immuno Dermatology Company Founded In February 2024With Headquarters In Bostonmassachusettsand Genevaswitzerlandthe Company Was Established Through The Merger Of Six Asset Centric Firms And Received $100 Million In Financing From Medicxialys Pharmaceuticals Focuses On Advancing Treatments For Various Dermatological Conditionsaddressing Significant Unmet Medical Needs The Company Specializes In Research And Developmentutilizing Multiple Platform Technologies To Create Innovative Treatments For Immune Inflammatory And Autoimmune Skin Diseasesalys Pharmaceuticals Has A Diverse Pipeline With Over A Dozen Programsincluding Aly 101Which Is Currently In A Phase Iia Trial For Alopecia Areatathe Company Aims To Achieve Ind Filings For All Programs And Complete Several Early Read Outs By The End Of 2026
